recormon ps 3000 u.i./0,3 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 3000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.15 mg, aqua ad iniectabile q.s. ad solutionem pro 0.3 ml corresp. natrium 0.48 mg. - la stimulation de l'Érythropoïèse - biotechnologika
recormon ps 5000 u.i./0,3 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 5000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.15 mg, aqua ad iniectabile q.s. ad solutionem pro 0.3 ml corresp. natrium 0.48 mg. - la stimulation de l'Érythropoïèse - biotechnologika
recormon ps 10'000 u.i./0,6 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 10000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.3 mg, aqua ad iniectabile q.s. ad solutionem pro 0.6 ml corresp. natrium 0.96 mg. - la stimulation de l'Érythropoïèse - biotechnologika
recormon ps 4000 u.i./0,3 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 4000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.15 mg, aqua ad iniectabile q.s. ad solutionem pro 0.3 ml corresp. natrium 0.48 mg. - la stimulation de l'Érythropoïèse - biotechnologika
recormon ps 6000 u.i./0,3 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 6000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.15 mg, aqua ad iniectabile q.s. ad solutionem pro 0.3 ml corresp. natrium 0.48 mg. - la stimulation de l'Érythropoïèse - biotechnologika
recormon ps 30'000 u.i./0,6 ml les seringues préremplies
roche pharma (schweiz) ag - epoetinum beta - les seringues préremplies - epoetinum beta 30000 u.i., ureum, natrii chloridum, polysorbatum 20, natrii dihydrogenophosphas dihydricus, dinatrii phosphas dodecahydricus, calcii chloridum dihydricum, glycinum, leucinum, isoleucinum, threoninum, acidum glutamicum, phenylalaninum 0.3 mg, aqua ad iniectabile q.s. ad solutionem pro 0.6 ml corresp. natrium 1 mg. - la stimulation de l'Érythropoïèse - biotechnologika
bendamustine sandoz 2,5 mg/ml, poudre pour solution à diluer pour perfusion
sandoz - chlorhydrate de bendamustine - poudre - 25 mg - composition pour un flacon de 20 ml > chlorhydrate de bendamustine : 25 mg - pharmacotherapeutique agents antinéoplasiques, agents alkylants
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - autres agents antinéoplasiques - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agents antinéoplasiques - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
shingrix
glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - l'herpès zoster - vaccins - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. l'utilisation de shingrix doit être en conformité avec les recommandations officielles.